GRFS - Grifols on go with hyperimmune globulin trial for COVID-19

Grifols (GRFS) has started a randomized clinical trial to test its safety, efficacy and tolerability of its anti-SARS-CoV-2 hyperimmune globulin, a potential treatment for COVID-19.This medicine provides a high and consistent concentration of purified neutralizing antibodies and could be used for both prevention and treatment of the disease.The Phase 3 trial, called Inpatient Treatment with Anti-Coronavirus Immunoglobulin ((ITAC)), will include 500 hospitalized adults with COVID-19.The company has collected convalescent plasma from healthy recovered COVID-19 donors for the trial.Wall Street sell-siders are Bullish with price target of $22.83 whereas Quant Rating is Neutral.

For further details see:

Grifols on go with hyperimmune globulin trial for COVID-19